154 related articles for article (PubMed ID: 14517707)
1. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.
Silveira P; Vaz-da-Silva M; Almeida L; Maia J; Falcão A; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):603-9. PubMed ID: 14517707
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa.
Almeida L; Vaz-da-Silva M; Silveira P; Falcão A; Maia J; Loureiro A; Torrão L; Machado R; Wright L; Soares-da-Silva P
Clin Neuropharmacol; 2004; 27(1):17-24. PubMed ID: 15090932
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
5. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.
Almeida L; Soares-da-Silva P
Drugs R D; 2003; 4(4):207-17. PubMed ID: 12848585
[TBL] [Abstract][Full Text] [Related]
7. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Soares-da-Silva P; Vieira-Coelho MA; Parada A
Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects.
Almeida L; Soares-da-Silva P
J Clin Pharmacol; 2003 Dec; 43(12):1350-60. PubMed ID: 14615471
[TBL] [Abstract][Full Text] [Related]
10. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
12. COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Gasser UE; Jorga K; Crevoisier C; Hovens SE; van Giersbergen PL
Eur Neurol; 1999; 41(4):206-11. PubMed ID: 10343151
[TBL] [Abstract][Full Text] [Related]
13. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
14. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
15. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
Dingemanse J; Jorga K; Zürcher G; Schmitt M; Sedek G; Da Prada M; Van Brummelen P
Br J Clin Pharmacol; 1995 Sep; 40(3):253-62. PubMed ID: 8527287
[TBL] [Abstract][Full Text] [Related]
17. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
[TBL] [Abstract][Full Text] [Related]
18. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Rocha JF; Sicard É; Fauchoux N; Falcão A; Santos A; Loureiro AI; Pinto R; Bonifácio MJ; Nunes T; Almeida L; Soares-da-Silva P
Br J Clin Pharmacol; 2017 Mar; 83(3):540-553. PubMed ID: 27763682
[TBL] [Abstract][Full Text] [Related]
19. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
20. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
